BECTON DICKINSON & CO (BDX)

Becton, Dickinson and Company (BD), incorporated in New Jersey in 1906, is a global medical technology company headquartered in Franklin Lakes, New Jersey, engaged in developing, manufacturing, and selling medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and consumers. As of September 30, 2025, BD operated through three segments—BD Medical, BD Life Sciences, and BD Interventional—though effective October 1, 2025, it reorganized into five segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences. BD Medical offers medication delivery and management solutions, pharmaceutical drug delivery systems, and advanced patient monitoring technologies, serving hospitals, physicians, pharmaceutical companies, and public health agencies.

BD Life Sciences provides diagnostic solutions, bioscience research tools, and specimen management products used in disease detection, cancer diagnostics, and cellular research. BD Interventional supplies surgical, peripheral intervention, and urology/critical care products for use in hospitals, surgery centers, and homecare settings. Key recent corporate developments include the September 2024 acquisition of Edwards Lifesciences' Critical Care product group (renamed BD Advanced Patient Monitoring) for $3.914 billion; a planned Reverse Morris Trust transaction announced in July 2025 to combine BD’s Biosciences and Diagnostic Solutions businesses with Waters Corporation, expected to close around Q1 calendar year 2026, with BD shareholders retaining about 39.2% ownership of the combined entity and BD receiving approximately $4 billion in cash proceeds; the 2023 divestiture of its Surgical Instrumentation platform for a $268 million pre-tax gain; and the 2022 spin-off of its Diabetes Care business as Embecta Corp. BD operates internationally across EMEA, Greater Asia, Latin America, and Canada, with manufacturing facilities in 18 countries outside the U.S., and distributes products through direct sales and independent distribution channels, with limited seasonality tied to products like flu diagnostics and certain medical devices.

The company sources diverse raw materials, including plastics, metals, and biological/chemical products, some of which are sole-sourced, requiring rigorous qualification processes for alternative suppliers. R&D is conducted primarily in North America, with additional centers in Asia and Europe, supported by collaborations with universities and research institutions. BD holds significant intellectual property, including patents and trademarks, though no single asset is deemed individually material.

The company operates in a highly competitive and regulated global medical technology market, facing pricing pressures, technological disruption, and evolving reimbursement policies from public and private payers worldwide. BD is subject to extensive regulation by the FDA and international authorities governing product development, manufacturing, and marketing. Notably, its U.S. infusion pump unit operates under an amended FDA Consent Decree (originally from 2007, related to Alaris infusion pumps), with ongoing compliance and remediation actions following multiple FDA Form 483 Notices and a November 2024 Warning Letter concerning its Dispensing quality management system and Pyxis products; the company has recorded a liability for estimated related costs.

BD also faces regulatory developments concerning ethylene oxide sterilization emissions, including new EPA standards effective 2024–2026, which may affect sterilization operations and costs, though BD has taken steps such as installing emissions controls and securing a temporary compliance exemption to mitigate potential impacts.